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Abstract
Introduction At physiologic concentration in serum, the bile
acid sodium deoxycholate (DC) induces survival and migration
of breast cancer cells. Here we provide evidence of a novel
mechanism by which DC reduces apoptosis that is induced by
the sphingolipid ceramide in breast cancer cells.
Methods Murine mammacarcinoma 4T1 cells were used in vitro
to determine apoptosis and alteration of sphingolipid
metabolism by DC, and in vivo to quantify the effect of DC on
metastasis.
Results We found that DC increased the number of intestinal
metastases generated from 4T1 cell tumors grafted into the fat
pad. The metastatic nodes contained slowly dividing cancer
cells in immediate vicinity of newly formed blood vessels. These
cells were positive for CD44, a marker that has been suggested
to be expressed on breast cancer stem cells. In culture, a
subpopulation (3 ± 1%) of slowly dividing, CD44+ cells gave
rise to rapidly dividing, CD44- cells. DC promoted survival of
CD44+ cells, which was concurrent with reduced levels of
activated caspase 3 and ceramide, a sphingolipid inducing
apoptosis in 4T1 cells. Z-guggulsterone, an antagonist of the
farnesoid-X-receptor, obliterated this anti-apoptotic effect,
indicating that DC increased cell survival via farnesoid-X-
receptor. DC also increased the gene expression of the vascular
endothelial growth factor receptor 2 (Flk-1), suggesting that DC
enhanced the initial growth of secondary tumors adjacent to
blood vessels. The Flk-1 antagonist SU5416 obliterated the
reduction of ceramide and apoptosis by DC, indicating that
enhanced cell survival is due to Flk-1-induced reduction in
ceramide.
Conclusions Our findings show, for the first time, that DC is a
natural tumor promoter by elevating Flk-1 and decreasing
ceramide-mediated apoptosis of breast cancer progenitor cells.
Reducing the level or effect of serum DC and elevating ceramide
in breast cancer progenitor cells by treatment with Z-
guggulsterone and/or vascular endothelial growth factor
receptor 2/Flk-1 antagonists may thus be a promising strategy
to reduce breast cancer metastasis.
Introduction
Breast cancer metastasis is a multi-step process that starts
with evasion of cancer cells from the primary tumor, migration
through the blood stream and lymphatic ducts, and homing
into critical target tissues, creating a life-threatening disease
[1]. In all of these steps, cancer cells are exposed to growth
factors and chemokines in the serum, vastly enhancing their
potential to proliferate and migrate. Most recently, our labora-
tory has shown that one of these factors is the bile acid sodium
deoxycholate (DC) [1]. DC is synthesized by bacteria in the
intestine and, like other bile acids, it facilitates dietary fat
processing. In blood, the normal serum concentration of DC is
about 5 to 10 mol/l, but increased levels of more than 50
mol/l have been determined in breast cyst fluid [2,3]. Histor-
ically, DC was among the first bile acids found to cause can-
cer, and it has been shown to promote colon carcinogenesis
[4,5]. Despite this evidence that DC is a physiological tumor
promoter, little is known about its effect on various types of
cancer cells.
BCPC: breast cancer progenitor cell; DC: sodium deoxycholate; FACS: fluorescence-activated cell sorting; FBS: fetal bovine serum; FXR: farnesoid 
X receptor; PBS: phosphate-buffered saline; PBST: phosphate-buffered saline containing 0.1% Tween-20; RT-PCR: reverse transcription polymer-
ase chain reaction; TUNEL: terminal dUTP nick-end labeling; uPA: urokinase like plasminogen activator; VEGF: vascular endothelial growth factor; 
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Previously, we showed that 10 mol/l DC enhances survival
and migration of human breast cancer MDA-MB-231 cells by
fivefold and 60%, respectively [1]. This anti-apoptotic and
chemokinetic effect was unexpected because numerous other
studies found that DC induced apoptosis in cancer cells [6-9].
The pro-apoptotic effect, however, relied on incubation with
up to 50-fold higher concentrations of DC than used in our
study. Our laboratory was also the first to show that the bile
acid receptor farnesoid X receptor (FXR) is expressed in
breast cancer cells, that DC induced translocation of FXR into
the nucleus, and that this increased the protein levels of urok-
inase like plasminogen activator (uPA) and its receptor [1]. In
particular, expression of uPA and uPA receptor are common to
metastatic cancers and help cancer cells to invade solid tis-
sues. The elevated gene expression of FXR as a tumor marker
in breast cancer has been confirmed by other groups [10-12].
It is not known, however, whether DC will also promote breast
cancer cell migration and metastasis in vivo.
In this study we used a well established orthotopic, syngeneic,
and metastatic murine 4T1 breast cancer model in Balb/c
mice [13-18]. The majority of metastatic tumor nodes were
observed in the intestine and liver, two tissues with high con-
centrations of DC. DC promoted survival and growth of slowly
dividing cancer cells that could self-renew and gave rise to
rapidly dividing breast cancer cells. The slowly dividing cells
expressed high levels of the vascular endothelial growth factor
(VEGF) receptor 2 (Flk-1) and the hyaluronic acid receptor
CD44 [19-21]. These data suggested that DC promoted the
proliferation of breast cancer cells, which formed metastases
at newly formed blood vessels. Although the expression of
CD44 has been attributed to a cancer stem cell-like pheno-
type and found to increase the invasive properties of breast
cancer cells, its role and prevalence in metastasis have been
controversial [19,22,23]. Cancer stem cells are self-renewing
cells that have been suggested to reside within tumors as a
source for cancer cells with limited capacity for repeated cell
division [20,24]. Our report is the first to show that breast can-
cer cell survival and metastasis is promoted by DC, and that
this effect is obliterated by the FXR antagonist Z-guggulster-
one. Our results may pave the way to novel options for breast
cancer treatment by blocking DC-induced survival of cancer
cells.
Materials and methods
Materials
4T1 mouse breast cancer cells were purchased from the
American Type Culture Collection (Manassas, VA, USA).
RPMI 1640 was from Cellgro (Herndon, VA, USA). Penicillin-
streptomycin and Vybrant CM-DiI and Vybrant CM-DiO cell
labeling solutions were from Invitrogen (Carlsbad, CA, USA).
Fetal bovine serum (FBS) was from Atlanta Biologicals (Law-
renceville, GA, USA). DC and the VEGF receptor (VEGFR)2/
Flk-1 antagonist SU5416 was from Sigma Aldrich (St. Louis,
MO, USA). Polyclonal anti- actin goat IgG, monoclonal anti-
 tubulin mouse IgG and monoclonal anti-Flk1 mouse IgG
were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA). Polyclonal anti-CD44 rabbit IgG was from Abcam
(Cambridge, MA, USA). Cleaved (active) caspase-3 antibody
was from Cell Signaling Technology (Beverly, MA, USA). Anti-
ceramide rabbit IgG was generated in our laboratory, as
described previously [25]. Anti-ceramide mouse IgM
(MAS00020) was from Glycobiotech (Kuekels, Germany). Z-
guggulsterone was obtained from EMD Biosciences (Gibbs-
town, NJ, USA). Horseradish peroxidase-conjugated anti-
mouse and anti-goat IgG, Cy3-conjugated donkey anti-rabbit
IgG, Cy2-conjugated donkey anti-mouse IgG, Cy2-conjugated
donkey anti-mouse IgM, -chain specific, Cy3-conjugated
goat anti-mouse IgG, and normal goat and donkey serum were
purchased from Jackson ImmunoResearch (West Grove, PA,
USA). The in situ terminal dUTP nick-end labeling (TUNEL) flu-
orescence staining kit was purchased from Oncogene
Research Products (San Diego, CA, USA).
Methods
Cultivation and treatment of breast cancer cells
4T1 cells were maintained in RPMI 1640 supplemented with
10% FBS and 1% antibiotic-antimycotic solution at 37°C in a
humidified atmosphere containing 5% carbon dioxide. Cells
were first cultivated in serum-free medium for 24 hours and
then treated with various concentrations of DC or other rea-
gents (for example, Z-guggulsterone, VEGFR-2 antagonist). A
stock solution of sodium DC (100 mmol/l) was prepared in
water and diluted in the medium to yield the desired final con-
centrations.
Cell labeling
Vybrant CM DiI and DiO are nontoxic, lipophilic, carbocyanine
dyes that bind to cellular phospholipid bilayer membranes and
are well suited for long-term labeling and tracking of cells. 4T1
cells were labeled with the cell labeling solutions in accord-
ance with the manufacturer's (Molecular Probes, Carlsbad,
CA, USA) instructions. Briefly, cells were dissociated by treat-
ment with trypsin and then resuspended at a density of 1 ×
106 cells/ml in serum-free RPMI medium. Cells were then
mixed with 5 l of Vybrant CM-DiI (red) or DiO (green) cell
labeling solutions per milliliter of cell suspension and incu-
bated at 37°C for 30 minutes. The labeled suspension was
mixed with serum-containing RPMI medium and centrifuged at
1,200 rpm for 5 minutes. The supernatant was removed and
the cells gently resuspended in warm medium. The wash pro-
cedure was repeated one more time before the cells were
plated. After 15 minutes recovery time, labeled cells were
observed under an Axiophot fluorescence microscope (Carl
Zeiss MicroImaging, Inc., Thornwood, NY, USA) to ensure that
all cells took up the dye. Under these conditions we usually
observed 100% labeling of cells.Available online http://breast-cancer-research.com/content/10/6/R106
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In vivo analysis of metastasis
The orthotopic 4T1 mouse breast cancer model in Balb/c
mice was used following published procedures [13]. This
study was approved by the Institutional Animal Care and Use
Committee of the Medical College of Georgia, Augusta, Geor-
gia, USA. The scheme of the in vivo model is represented in
Figure 1a. Briefly, 106 4T1 cells were injected into the flanks
of Balb/c mice to grow the primary tumor. After 10 to 14 days,
tumor tissue was dissected out of the flanks and chopped into
small fragments using a surgical blade. Small pieces of
approximately 100 cells were labeled with Vybrant CM-DiI
(>90% of the cells were labeled), loose cells removed, and the
tissue fragments injected into the fat pad (10 pieces/injection)
of another Balb/c mouse. Mice (12 in each group) were either
injected with vehicle or treated with DC (four intraperitoneal
injections of 25 mg/kg per 48 hours starting 24 hours after
grafting into fat pad). Two weeks after grafting, mice were
killed and the internal organs removed. Metastatic tumor nod-
ules on various organs were counted and analyzed using fluo-
rescence microscopy (to locate Vybrant CM DiI-labeled cells).
Vybrant CM-DiI cells within a tumor nodule (0.8 ± 0.2 mm
diameter) were quantified by crysectioning five nodules at 10
Figure 1
DC promotes secondary tumor formation from fat pad grafts of 4T1 cells DC promotes secondary tumor formation from fat pad grafts of 4T1 cells. (a) 4T1 tumor and metastasis model. 4T1 cells were injected into the 
flanks of Balb/c mice. Tumor tissue was extracted from the flanks and chopped into small fragments. Cells were labeled with Vybrant CM-DiI. The 
labeled tissue fragments were grafted into the fat pads of another series of mice, which were then intraperitoneally injected with vehicle or treated 
with DC. After 14 days, mice were killed and secondary tumors quantified. (b) Brightfield and epifluorescence (Vybrant CM-DiI) image of secondary 
tumor in lung (arrow points at blood vessel). Scale bar = 1.0 mm. (c) Epifluorescence image (Vybrant CM-DiI) in intestine (arrows point at tumor nod-
ules). Scale bar = 1.0 mm. (d) Image as in panel c, but overlay with phase contrast image (arrows point at Vybrant CM DiI-labeled cells [red]). Scale 
bar = 200 m. (e) Mice were treated as described for panel a and the number of secondary tumor nodules in the intestine determined. DC, sodium 
deoxycholate.Breast Cancer Research    Vol 10 No 6    Krishnamurthy et al.
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m and counting fluorescent cells in consecutive sections
throughout the tumor.
Hoechst exclusion assay
4T1 cells (living culture) were incubated with 5 g/ml Hoechst
33342 dye for 30 to 60 minutes at 37°C following a modified
protocol previously published [26]. The Hoechst staining was
monitored by fluorescence microscopy using the DAPI chan-
nel. Micrographs were taken when there was a clear difference
in the intensity of the fluorescence signal between slowly and
rapidly dividing cells. Slowly dividing cells were identified by
staining for Vybrant CM-diI.
Immunocytochemistry and flow cytometry
For immunocytochemistry, cells were grown on coverslips and
cultivated in the absence or presence of DC or other reagents.
Cells were fixed with 4% p-formaldehyde in phosphate-buff-
ered saline (PBS) for 20 minutes and then permeabilized by
incubation with 0.2% Triton X-100 in PBS for 5 minutes at
room temperature. Nonspecific binding sites were saturated
using a blocking solution of 3% ovalbumin/2% donkey serum
in PBS. Primary and secondary antibodies were diluted in
0.1% ovalbumin/PBS. Cells were stained with Hoechst to vis-
ualize the nuclei. Epifluorescence microscopy was performed
with an Axiophot microscope (Carl Zeiss MicroImaging, Inc.)
equipped with a Spot II CCD camera. Confocal fluorescence
microscopy was performed using a Zeiss LSM510 confocal
laser scanning microscope equipped with a two-photon argon
laser at 488 nm (Cy2), 543 nm (Cy3), or 633 nm (Cy5, Alexa
Fluor 647), respectively.
For flow cytometric analysis, cells were detached using 0.5
mmol/l EDTA/10% FBS and passed through a 40 m mesh.
The cells were resuspended in 100 l of blocking buffer (3%
ovalbumin in PBS) and nonspecific binding sites saturated by
incubation for 15 minutes at room temperature. The cells were
incubated with primary antibodies (rabbit anti-CD44, 1:50;
mouse anti-Flk1, 1:50) and secondary antibodies (Alexa 488
anti-mouse, 1:100; Alexa 647 anti-rabbit, 1:100) diluted in
0.5% ovalbumin/PBS at 4°C for 60 minutes and 45 minutes,
respectively. Cells were then washed with PBS, centrifuged,
resuspended in 500 l PBS, and analyzed using a Becton
Dickinson FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA, USA). Unstained cells were processed similarly,
except that in place of primary antibodies they were incubated
with 0.5% ovalbumin/PBS. The unstained cells and cells
stained with a single combination of primary and secondary
antibodies were used to set the gates for the analysis of dou-
ble stained cells.
RT-PCR
Total RNA was prepared from control and DC treated cells
using Trizol, following the manufacturer's (Invitrogen) protocol.
First strand cDNA was synthesized using Omniscript RT Kit, in
accordance with the manufacturer's (Qiagen, Valencia, CA,
USA) protocol. PCR was performed for 25 cycles using the
following oligonucleotide primers and annealing temperatures:
-actin (sense, 5'-tgacggggtcacccacactgtgcccatcta-3'; anti-
sense, 5'-ctagaagcatttgcggtggacgatggaggg-3'; 56°C) and
Flk1 (sense, 5'-taagggcatggagttcttgg-3'; antisense, 5'-cagag-
caacacaccgaaaga-3'; 53°C). The amount of template from
each sample was adjusted until PCR yielded equal intensities
of amplification for -actin.
Western blot analysis
For immunoblot analysis, protein concentrations were deter-
mined using the Rc/Dc Protein Assay, in accordance with the
manufacturer's (BioRad Laboratories, Inc., Hercules, CA,
USA) instructions. Equal amounts of protein were loaded on a
4% to 20% gradient gel and SDS-PAGE was performed using
the Laemmli method. For immunoblotting, membranes were
first blocked with 5% dry milk in PBST (PBS containing 0.1%
Tween-20) and incubated with primary antibodies (anti-Flk1,
1:1,000; anti-active caspase 3, 1:500) diluted in the blocking
buffer overnight at 4°C. Membranes were then washed with
PBST three times and incubated with the appropriate horse-
radish peroxidase-conjugated secondary antibodies (1:2,000)
for 1 hour at room temperature. Membranes were washed with
PBST at room temperature three times (15 minutes each).
Bands were detected by using a chemiluminescence system
and exposure to X-ray film. Membranes were then stripped and
re-probed, as described above, with either anti--actin
(1:1,000) or anti--tubulin (1:1,000) to confirm equal loading.
Ceramide analysis by high-performance thin layer 
chromatography
Total lipids were extracted from cells by sonicating cell pellets
in a mixture of chloroform:methanol (2:1; vol/vol). After 1 hour
of extraction (on a magnetic stirrer), the solution was centri-
fuged at 4,000 rpm for 10 minutes. The supernatant was
transferred to a clean glass tube, whereas lipids from the pellet
were re-extracted in chloroform:methanol (2:1; vol:vol) for 1
hour. The resulting solution is centrifuged again and the super-
natant pooled with the supernatant from the first extraction.
The pellet is dried down, dissolved in 2% SDS, and used for
protein estimation using BCA method (Pierce, Rockford, IL,
USA). The supernatant is dried down completely and resus-
pended in a small volume, based on total protein content of the
sample. These samples were resolved by high-performance
thin layer chromatography using the running solvent chloro-
form:methanol:acetic acid (95:4.5:0.5; vol:vol) for the separa-
tion of ceramide. Individual bands were visualized by staining
with 3% cupric acetate in 8% phosphoric acid and identified
by comparing them to the migration distance of standard cera-
mide [1].
Analysis of cell death
For the analysis of cell death, cells were incubated in the
absence of serum with or without the addition of DC or other
reagents. At the end of the treatment period, cells wereAvailable online http://breast-cancer-research.com/content/10/6/R106
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detached by trypsinization and pooled with floating cells col-
lected from the medium. Cells were washed with PBS and
stained with propidium iodide for 30 minutes at room temper-
ature. Cells were washed with PBS and analyzed by flow
cytometry to measure cell death. Results are represented as
mean ± standard deviation of four independent experiments.
Results and discussion
DC promotes the formation of secondary tumors 
containing slowly dividing, CD44+/Flk-1+ 4T1 cells
Previously, we reported that DC increases cell survival and
migration of MDA-MB-231 cells in vitro [1]. To test the effect
of DC on tumor formation in vivo, we used a well established
syngeneic and orthotopic 4T1 mouse breast cancer cell model
in Balb/c mice [13]. 4T1 cells were injected into the flanks of
Balb/c mice and a primary tumor generated (Figure 1a). Pri-
mary tumor tissue was extracted from the flanks and chopped
into small fragments. Cells in the tissue fragments were
labeled with the vital fluorescent dye Vybrant CM-DiI and
injected into the fat pads of another series of mice (Figure 1a).
Engraftment was confirmed by analyzing tumor nodules in the
fat pad. The flank-to-fat pad graft procedure ensured that cells
in secondary tumors were truly emigrating from the fat pad
graft and were not just diffusing as single cells. DC was admin-
istered intraperitoneally at a dose of 25 mg/kg every other day.
After secondary tumors had formed, mice were killed and the
tumor nodules analyzed using fluorescence microscopy. Sec-
ondary tumor nodules were detected in lung (Figure 1b), liver,
bone, and intestine (Figures 1c, d and 2a; Figure 2a shows
phase contrast and Figure S1A [see Additional data file 1]
shows hematoxylin and eosin staining of a cryosection). Figure
1e shows that treatment with DC increased the number of
intestinal tumor nodules by threefold, suggesting that DC pro-
moted cell survival, proliferation, or migration of 4T1 cells.
In each primary tumor nodule in the fat pad and in the second-
ary tumor nodules derived from them, we detected a group of
Vybrant CM DiI-labeled cells (0.3 ± 0.1% of total cells in a sec-
ondary tumor nodule) surrounded by unlabeled cancer cells
that formed the majority (>99% of all cells) of the tumor mass
(Figures 1d and 2b). Only labeled cells were able to generate
unlabeled progeny cells by repeated cell division, whereas
unlabeled cells could not convert into labeled cells. Because
each secondary nodule contained Vybrant CM DiI-labeled
cells, our results suggest that a portion of labeled cells
migrated from the fat pad to the intestine and divided slowly,
as may be concluded from the retention of the Vybrant CM-DiI
fluorescence. However, these cells also gave rise to rapidly
dividing cancer cells, forming the major tumor mass, which lost
the fluorescent signal due to dilution of the dye. Alternatively,
labeled and unlabeled cells may have migrated together and
formed a secondary tumor containing unlabeled cells outgrow-
ing the labeled cells. However, the probability of this event
would not be higher than that of single cell migration. Because
the secondary tumors contained a portion of labeled cells it is
rather likely that these tumors were formed from labeled cells
that divided asymmetrically and gave rise to rapidly dividing
cells that became unlabeled.
The transition of slowly to rapidly dividing cells has been
hypothesized to be characteristic for cancer stem cells
[20,24]. The expression of CD44 is another marker that has
been used to identify cancer stem cells [21,22]. We cryosec-
tioned the tumor nodules and determined the expression of
CD44 using immunocytochemistry. Figure 2b, c shows that
the Vybrant CM DiI-stained cells were co-stained for CD44,
suggesting that they showed a feature of cancer stem cells
[see Figure S1B in Additional data file 1 for individual color
channels] [20,21,27]. Because these cells were always
located in close vicinity to blood vessels, we determined the
expression of Flk-1, a VEGF receptor (VEGFR2) expressed in
4T1 cells [28,29]. Indeed, Vybrant CM-DiIhigh/CD44+ cells
were also positive for Flk-1 (Figure 2b). In summary, these
results suggested that a subpopulation of slowly dividing cells
formed secondary tumor modules after having emigrated from
the primary nodules in the fat pad graft. Further, our data indi-
cate that migration or metastasis of these cells was promoted
by DC.
4T1 cancer cells divide asymmetrically in vitro
Retention of Vybrant CM-DiI in a subpopulation of cells within
the secondary tumors suggested that slowly dividing cells self-
renewed and gave rise to rapidly dividing cells by asymmetric
cell division. To test this hypothesis in vitro, 4T1 cells were
labeled with Vybrant CM-DiI and seeded as single cells in
each well of 48-well plates. Figure 3 shows that colonies with
two distinct phenotypes were formed: 46 out of 48 colonies
showed homogenous distribution of Vybrant CM-DiI staining
(Figire 3a) and, eventually, the fluorescence signal was no
longer detectable (Figure 3a); and two out of 48 colonies
showed retention of Vybrant CM-DiI in a few cells, whereas the
fluorescent label was rapidly lost in the rest of the colony (Fig-
ure 3b). As depicted in Figure S2 [see Additional data file 1],
this distribution of the fluorescent label was attributed to two
distinct modes of cell division: single rapidly dividing cells
once again gave rise to other rapidly dividing cells; and single
slowly dividing cells gave rise to another group of slowly divid-
ing cells and the majority of rapidly dividing cells. The possibil-
ity that labeling cells with the vital dye slowed down cell
division was ruled out by comparing the growth rates of
labeled and unlabeled cells, which was not found to be differ-
ent (data not shown). Furthermore, Vybrant CM-DiI and its flu-
orescent analogs (for instance, DiO) have been widely used to
label cells and track cell lineage, migration, and tumor growth
in several previous studies, without reported toxicity or nega-
tive effects on growth rate [30-32].
The observation that slowly dividing cells gave rise to rapidly
dividing cells suggested that the slowly dividing cells divided
asymmetrically; one daughter cell remained slowly dividingBreast Cancer Research    Vol 10 No 6    Krishnamurthy et al.
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Figure 2
Secondary tumors contain slowly dividing CD44+/Flk-1+ cells Secondary tumors contain slowly dividing CD44+/Flk-1+ cells. (a) Cryosection of secondary tumor nodule in intestine (differential contrast). The 
white box shows an area that is further characterized in panel b. Scale bar = 100 m. (b) Cryosection as in panel a used for immunocytochemistry. 
Note that Vybrant CM DiI-labeled cells (left panel [red]) express CD44 (right panel [red]) and Flk-1 (right panel [green]). Scale bar = 20 m. (c) 
Another area of the secondary tumor model at higher magnification showing co-distribution of Vybrant-CM DiI and CD44. Preservation of Vybrant 
CM-DiI staining indicates slow cell division. Scale bar = 5 m.Available online http://breast-cancer-research.com/content/10/6/R106
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and therefore retained the fluorescence, whereas the other
daughter cell started to divide rapidly and therefore diluted the
fluorescent dye over the entire progeny until the label was no
longer detectable [see Figure S2 in Additional data file 1]. We
then determined whether asymmetric cell division was a stable
feature of slowly dividing cells. Alternatively, rapidly dividing
cells could become slowly dividing cells and therefore retain
fluorescence [see Figure S2 in Additional data file 1]. To test
this, we dissociated colonies from the first round of Vybrant
CM-DiI labeling, labeled all of the cells with DiO (green fluo-
rescent analog of Vybrant CM-DiI), and again seeded single
cells into 48-well plates. The colonies derived from rapidly
dividing cells gradually lost green fluorescence, indicating that
they continued to divide rapidly (Figure 3c). However, single
slowly dividing cells gave rise to rapidly and slowly dividing
cells that lost or retained green (DiO) fluorescence, respec-
tively. At the same time, the slowly dividing cells showed resid-
ual Vybrant CM-DiI fluorescence from the first round of colony
formation (Figure 3d, arrow). This observation was best
explained by the assumption that asymmetric cell division was
specific for the subpopulation of slowly dividing cells. To test
asymmetric cell division further, slowly dividing, Vybrant CM-
DiI-labeled cells were separated using fluorescence-activated
cell sorting (FACS) and then re-plated at clonal density. Flow
cytometry and fluorescence microscopy showed that the
progeny distributed into labeled and unlabeled cells at a simi-
Figure 3
Slowly dividing cells divide asymmetrically Slowly dividing cells divide asymmetrically. (a, b) 4T1 cells were labeled with Vybrant CM-DiI (red fluorescence) and then single cells were 
seeded into individual wells of 48-well plates (one cell/well). (Panel a) Forty-six out of 48 wells showed homogenous distribution of Vybrant CM-DiI 
to the daughter cells (rapidly dividing cells). (Panel b) Two out of 48 wells showed a few highly labeled cells (slowly dividing cells), whereas the rest 
of the colony became gradually unlabeled (rapidly dividing cells). This heterogeneous distribution of Vybrant CM-DiI suggests asymmetric cell divi-
sion of slowly dividing cells giving rise to one daughter cell that stays slowly dividing and retains the label (self-renewing cell), whereas the other 
daughter cell converts into a rapidly dividing cell. (c, d) Colonies as shown in panels a and b were dissociated, labeled with DiO (green fluores-
cence), and again seeded as single cells (one cell/well). (Panel c) Colonies formed from rapidly dividing cells (no red fluorescence) continued to 
divide rapidly and showed homogenous distribution of DiO until the fluorescence signal was diluted below the threshold of detection. (Panel d) Col-
onies formed from slowly dividing cells (red fluorescence from Vybrant CM-DiI labeling was still visible) again showed asymmetric cell division giving 
rise to slowly dividing cells that were labeled with both Vybrant CM-DiI and DiO (arrow), and rapidly dividing cells that became unlabeled. A sche-
matic representation is provided in the additional materials [see Figure S2 in Additional data file 1]. Scale bars = 5 m.Breast Cancer Research    Vol 10 No 6    Krishnamurthy et al.
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lar proportion (3 ± 1% retained Vybrant CM-DiI fluorescence)
as the cells before FACS (Figure 4a, b). This result suggests
that the subpopulation of slowly dividing cells divided asym-
metrically and gave rise to self-renewing, slowly dividing
daughter cells, while providing the majority of rapidly dividing
cancer cells.
To test whether the subpopulation of slowly dividing cells
showed other proposed characteristics of cancer stem cells
we used two assays: Hoechst exclusion and immunostaining
for CD44 and CD24. Some cancer stem cells are known to
show less intense staining of nuclear DNA with Hoechst dye
because of the expression of the drug resistance transporter
(ATP-binding cassette or ABC proteins) [24,33]. Figure 4a
shows that cells with an intense fluorescence signal for
Vybrant CM-DiI showed none or only a low signal for Hoechst.
This result suggested that slowly dividing, DiI-labeled cells
exhibited a typical feature of cancer stem cells. Hoechst exclu-
sion was also found with a FACS fraction of highly DiI-labeled
cells, but not with unlabeled cells, demonstrating that this fea-
ture was typical for the slowly dividing subpopulation of 4T1
cells (Figure 4b).
Slowly dividing, DiI-labeled 4T1 cells were immunostained for
CD44, whereas unlabeled cells were not (Figure 4c). Consist-
ent with previous studies [34,35], immunostaining for CD24
Figure 4
Slowly dividing CD44+/Flk-1+ cells show characteristics of stem-like cancer cells Slowly dividing CD44+/Flk-1+ cells show characteristics of stem-like cancer cells. (a) Hoechst exclusion assay. Vybrant CM DiI-labeled cells 
were seeded at clonal density and allowed to propagate until reaching 70% confluence. Hoechst exclusion (arrows) was only found in slowly divid-
ing cells that retained Vybrant CM-DiI staining. Scale bar = 5 m. (b) Cells were cultivated as described for panel a and then FACS sorted for high 
Vybrant CM-DiI staining. After re-cultivation of this cell fraction, Hoechst exclusion (arrows) was again found only in cells that retained Vybrant CM-
DiI staining. Scale bar = 5 m. C. Immunocytochemistry for CD44 and CD24. Note that CD24 shows background expression and that CD44 and 
Vrybrant CM-DiI are co-distributed (purple in overlay). Scale bar = 20 m. FACS, fluorescence-activated cell sorting.Available online http://breast-cancer-research.com/content/10/6/R106
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was moderate and did not show preference for co-distribution
with CD44+ or CD44- cells (Figure 4c). The lack of CD24 in
CD44+ cells is one characteristic of human cancer stem cells,
but it is not commonly observed in stem-like cancer cells in
mouse [27,34,35]. When cultivated at clonal density, DiIhigh/
CD44+ cells lost the cell surface expression of CD44 after one
or two cell divisions, resulting in progeny cells with increased
proliferation rate. This was concurrent with loss of Vybrant
CM-DiI staining. Taken together, our results indicated that
slowly dividing, Hoechst-/DiIhigh/CD44+ cells showed two fea-
tures expected from breast cancer stem cells (Hoechst exclu-
sion and CD44 expression). In addition, these cells were self-
renewing and converted into rapidly dividing Hoechst+/DiIlow/
CD44- cancer cells. However, further studies will be required
to determine whether the subpopulation of slowly dividing 4T1
cells are genuine cancer stem cells.
DC elevates the expression of Flk-1 and increases 
survival of 4T1 cells by reducing ceramide
In secondary tumors, DiI+-labeled cells were found adjacent to
newly formed blood vessels (Figure 1b–d). These cells were
also stained for CD44 and Flk-1 (Figure 2b, c). Because DC
elevated the number of secondary tumors, we tested whether
DC enhanced the expression of Flk-1 in 4T1 cells, thereby
potentially promoting tumor growth by VEGF [28]. Figure 5a,
b shows that incubation of serum-free 4T1 cells with DC
increased the mRNA and protein levels of Flk-1. The bile acid
receptor (FXR) blocker Z-guggulsterone reduced the DC-
induced elevation of Flk-1 protein to less than control levels
Figure 5
DC promotes expression of Flk-1, which is prevented by Z-guggulsterone DC promotes expression of Flk-1, which is prevented by Z-guggulsterone. (a) RT-PCR for the expression of Flk-1 in 4T1 cells. (b) Immunoblot 
for the expression of Flk-1. (c) Flow cytometry for the expression of CD44 and Flk-1 in 4T1 cells cultivated in serum-free medium with or without DC. 
Note that CD44 and Flk-1 were co-expressed. DC, sodium deoxycholate; Gug, guggulsterone (50 mol/l).Breast Cancer Research    Vol 10 No 6    Krishnamurthy et al.
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(Figure 5b). This reduction was consistent with the findings of
a recent study [36] that showed that Z-guggulsterone reduces
Flk-1 expression and angiogenesis in endothelial cell culture.
Flow cytometry and immunocytochemistry showed that Flk-1
and CD44 were co-expressed (Figures 5c and 6a). This find-
ing was consistent with that observed with secondary tumors
(Figure 2b), suggesting that Flk-1+  cells showed CD44
expression as one feature found in stem-like cancer cells.
CD44+ cells also expressed the Flk-1 ligand VEGF, which is
consistent with its autocrine prosurvival effect found in cancer
cells (Figure 6b) [37].
Because DC elevated the expression of the prosurvival factor
Flk-1, we tested whether DC reduced cell death via VEGF/Flk-
1-dependent cell signaling. Incubation with 30 or 100 mol/l
DC for 48 hours reduced the number of dead (propidium
iodide stained) cells by 50% or 80%, respectively (Figure 7a).
The Flk-1 antagonist SU5416 completely obliterated the pro-
tective effect of DC, suggesting that VEGF and Flk-1 are
required for DC-mediated survival of CD44+ cells. Although
SU5416 also antagonizes Flt-3 and c-kit, the observations that
DC elevated the expression of Flk-1 and that SU5416 obliter-
ated DC-mediated cell survival suggest that SU5416 acted
specifically on Flk-1 [31,38]. To identify the mechanism under-
lying DC-enhanced cell survival, we tested activation of cas-
pase 3 and the level of ceramide, a sphingolipid that induces
apoptosis in a variety of cancer cell types [39-42]. Immunob-
lotting showed that 100 mol/l DC inhibited activation of cas-
pase 3 induced by serum deprivation (Figure 7b). High-
performance thin layer chromatography showed that, when
cultivated in serum-free medium, the ceramide level of 4T1
cells increased by fourfold (lane 3, Figure 7c) over serum con-
trols (lane 2, Figure 7c). DC (100 mol/l) reduced the cera-
mide level (lane 4) to less than half of that found with serum-
free cells. This effect was obliterated by SU5416 (Figure 7d),
Figure 6
VEGF and Flk-1 are both expressed in slowly dividing cells VEGF and Flk-1 are both expressed in slowly dividing cells. (a) Immunocytochemistry (confocal) for Flk-1 (green) and CD44 (red). Consistent 
with the results from flow cytometry (Figure 5c), both antigens were co-expressed in slowly dividing cells. Scale bar = 20 m. (b) Immunocytochem-
istry as in panel a, showing Hoechst staining of nuclei. Scale bar = 5 m. (c) Immunocytochemistry for VEGF (green) indicated that it is also 
expressed in slowly dividing (Vybrant CM-DiI labeled [red]) cells. Scale bar = 20 m. VEGF, vascular endothelial growth factor.Available online http://breast-cancer-research.com/content/10/6/R106
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which is consistent with the observation that SU5416
reversed DC-induced cell survival.
We then used two anti-ceramide antibodies (rabbit IgG gener-
ated in our laboratory and mouse IgM MAS00020) to detect
ceramide-containing 4T1 cells using immmunocytochemistry.
Figure 8a–d shows that CD44+  cells, in particular in the
periphery of CD44+ cell clusters, expressed high levels of
ceramide and underwent apoptosis after serum deprivation, as
determined by TUNEL assays (white staining in overlay; Figure
8b, middle panel). Incubation with 100 mol/l DC prevented
apoptosis of these cells and resulted in expansion of rapidly
dividing CD44- cells surrounding the CD44+ cell clusters.
Apoptosis was restored when cells were incubated with Z-
guggulsterone or C2-ceramide (not shown). In summary, our
results suggest that DC-induced elevation of (activated) Flk-1
Figure 7
DC prevents apoptosis by reduction in ceramide; blocking Flk-1 increases ceramide DC prevents apoptosis by reduction in ceramide; blocking Flk-1 increases ceramide. (a) Apoptosis induced by serum deprivation was quanti-
fied by propidium iodide staining and flow cytometry. DC was added to test its dose-dependent effect on the prevention of apoptosis. (b) Immunob-
lot for activated caspase 3. Cells were deprived of serum, lysed, and the protein analyzed by SDS-PAGE/immunoblotting. Note that the addition of 
100 mol/l DC suppressed activation of caspase 3, which was consistent with prevention of apoptosis (see panel a). (c) HPTLC analysis of cera-
mide. Cells were cultivated in the absence of serum and treated with reagents as indicated in the figure. Cellular lipids were then isolated and ana-
lyzed by HPTLC. Note that serum deprivation leads to the elevation of ceramide by fourfold. DC suppresses this elevation by 70%. (d) HPTLC 
analysis of ceramide as in panel c. Note that the Flk-1 antagonist SU5416 (10 mol/l) obliterated DC-induced reduction of ceramide. DC, sodium 
deoxycholate; HPTLC, high performance thin layer chromatography.Breast Cancer Research    Vol 10 No 6    Krishnamurthy et al.
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Figure 8
Ceramide is elevated in CD44+ cells, which is suppressed by DC Ceramide is elevated in CD44+ cells, which is suppressed by DC. (a) 4T1 cells were cultivated in serum-free medium and immunocytochemistry 
was performed for ceramide (blue) and CD44 (red). Apoptotic cells were identified by TUNEL staining (green). Note that CD44+ cells contained 
high levels of ceramide, which induced apoptosis in the periphery of CD44+ cell clusters (left panel). Ceramide elevation and apoptosis was pre-
vented by DC (right panel). Scale bar = 100 m. (b) Immunocytochemistry as in panel a (without DC), showing three optical planes as obtained from 
confocal laser scanning immunofluorescence microsocopy (Z-scan). Note that CD44+/ceramide+/TUNEL+ cells are located at the periphery of 
CD44+ cell clusters. Scale bar = 20 m. (c) Immunocytochemistry as in panel a, showing Hoechst staining of nuclei. Note that the majority of the 
CD44+/ceramide+ cells were apoptotic (TUNEL+), unless cells were incubated with DC (panels on the right). Scale bar = 10 m. (d) Confocal scan-
ning as described in panel b, but reconstruction of the fluorescent signal distribution in a Z-scan (z-axis is shown). Note that the peripheral distribu-
tion of ceramide+/TUNEL+ cells is consistent with the results shown in panel b. Scale bar = 10 m. DC, sodium deoxycholate; TUNEL, terminal 
dUTP nick-end labeling.Available online http://breast-cancer-research.com/content/10/6/R106
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leads to the reduction in pro-apoptotic ceramide, which pro-
motes survival of CD44+ breast cancer cells and rapid expan-
sion of their CD44- progeny cells.
Conclusion
In our previous studies we showed that the secondary bile
acid DC induces migration and promotes survival of human
breast cancer MDA-MB-231 cells [1]. To determine the effect
of DC on tumor growth in vivo, we used murine 4T1 cells in a
syngeneic mouse model for breast cancer metastasis. The
4T1 model does not need immunocompromised mouse hosts
and shows rapid metastasis to all inner organs and bone,
which is not completely achievable with MDA-MB-231 cells.
Using this model, we found that DC increases the numbers of
metastatic nodes, clearly showing that DC promotes tumori-
genesis and/or metastasis from 4T1 cells.
This result is consistent with data obtained in vitro showing
that DC protects 4T1 cells from apoptosis induced by serum
deprivation. The protective concentration is higher than that
found with MDA-MB-231 cells, which may be due to cell-spe-
cific differences between human and mouse breast cancer
cells. This concentration is within the range of that found for
bile acid elevation in breast cyst fluid, which has been sug-
gested to increase the risk for breast cancer [2]. Most intrigu-
ingly, our results demonstrate that bile acids, in particular DC,
are not a priori pro-apoptotic, but they may very well support
survival and metastasis of breast cancer cells in vitro and in
vivo.
Several lines of evidence suggest that in vivo, secondary
tumors are initiated by a specific subpopulation of slowly divid-
ing, self-renewing cancer cells. First, each of the intestinal
tumor nodules contains Vybrant CM DiI-labeled cells that can
only originate from labeled cells having emigrated from the fat
pad graft. Because these cells retain staining, but at the same
time are surrounded by nonlabeled tumor cells derived from
them, they have divided asymmetrically. Second, the slowly
dividing, Vybrant CM DiI-labeled cells are positive for CD44,
which has been proposed to be a stem cell marker. Finally, it
is known from a variety of stem or progenitor cell types that
VEGF isoforms and their receptors are co-expressed with
CD44 and that VEGF is an essential autocrine and anti-apop-
totic factor in 4T1 cells [37,43-46]. These observations
prompted us to determine DC-induced survival of a subpopu-
lation of CD44+ cells in a 4T1 cell culture.
It has been reported for endothelial cells that inhibition of Flk-
1 induces elevation of ceramide, leading to apoptosis by acti-
vation of caspase 3 [47,48]. Because VEGF and Flk-1 are co-
expressed in 4T1 cells, we tested whether the anti-apoptotic
effect of DC involves elevation of Flk-1 and reduction in cera-
mide and active caspase 3. Flk-1 is specifically expressed in
CD44+ cells, suggesting that stem-like cancer cells are pro-
tected by DC-induced elevation of Flk-1. However, when
counting CD44+/Flk-1+ cells we found that the proportion of
these cells was not increased. Therefore, we conclude that
DC increases the expression level of Flk-1 in CD44+ cells with-
out increasing the number of these cells. Alternatively, the
number of CD44+/Flk-1+ cells is initially increased, but then
these cells rapidly convert into CD44-/Flk-1- cancer cells.
Figure 9 shows a model that delineates how DC-induced
reduction of ceramide will lead to survival of peripheral CD44+
cells, which is then followed by rapid conversion into CD44-
cells. In the case that ceramide is elevated in the peripheral
cells, they undergo apoptosis by caspase 3 activation. Only
self-renewing (stem-like?) cancer cells in the center of the
CD44+ cell clusters persist. However, if ceramide is reduced,
then peripheral cells may divide asymmetrically giving rise to
self-renewing CD44+ and rapidly dividing CD44- cancer cells.
Most intriguingly, we have found a similar mechanism for cera-
mide-induced apoptosis in asymmetrically dividing, embryonic
stem cell derived cells that undergo apoptosis versus differen-
tiation to neural progenitor cells [49]. These cells divide asym-
metrically giving rise to one daughter cell that dies from
ceramide-induced apoptosis, whereas the other one survives,
proliferates, and then terminally differentiates. It is quite possi-
ble that the surviving neural progenitor cells behave similarly to
the breast tumor cells or breast cancer progenitor cells
Figure 9
Model for DC-sustained cell survival by reduction in ceramide-induced  apoptosis in BCPCs Model for DC-sustained cell survival by reduction in ceramide-
induced apoptosis in BCPCs. Initially, CD44+ stem-like cancer cells 
are low in ceramide and show asymmetric cell division, giving rise to 
one stem-like cancer cell and one breast cancer progenitor cell 
(BCPC). Serum deprivation (growth factor withdrawal) and loss of 
VEGF receptor (VEGFR) activation leads to increased ceramide levels 
and the induction of apoptosis in BCPCs. DC induces VEGFR expres-
sion, which prevents ceramide elevation and apoptosis in BCPCs, and 
promotes metastasis and growth of secondary tumors. Apoptosis is 
restored by blocking the DC receptor FXR with Z-guggulsterone (Z-
Gug) or inhibiting VEGFR with SU5416. BCPC, breast cancer progen-
itor cell; Cer, ceramide; DC, sodium deoxycholate; FXR, farnesoid X 
receptor; VEGFR, vascular endothelial growth factor receptor;Breast Cancer Research    Vol 10 No 6    Krishnamurthy et al.
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(BCPCs) in that prevention of ceramide-induced apoptosis
promotes survival and proliferation of the progenitor cells.
Unlike neural progenitor cells, however, BCPCs do not
become postmitotic and differentiate in a controlled way, but
continue to divide for numerous cell cycles and grow a tumor
mass.
This is the first report describing that DC reduces ceramide-
induced apoptosis in breast cancer cells. With respect to
tumor stem cells, we propose that ceramide elevation may
eliminate BCPCs, which is blocked by DC. Our results sug-
gest that VEGF/Flk-1 is a key factor in DC-induced reduction
in ceramide. The effect of Z-guggulsterone on the protein level
of Flk-1 and the Flk-1 antagonist SU5416 on ceramide and
apoptosis suggests that DC promotes cell survival via a novel
FXR-to-Flk-1 cell signaling pathway reducing pro-apoptotic
ceramide in BCPCs.
Our study also suggests that administration of Z-guggulster-
one and reducing serum bile acid levels could be useful in low-
ering the risk for metastasis. This hypothesis is consistent with
recent studies reporting that Z-guggulsterone induces apop-
tosis in breast cancer cells and that probiotic administration of
lactobacillus reduces serum DC and breast tumor growth in
mice [50-54]. Although the direct causal link between the
reduction of DC levels and tumor growth has not yet been
demonstrated in these models, these results are consistent
with epidemiological studies showing that the risk of breast
cancer is lower in women who have consumed lactobacillus-
containing food (for example, yoghurt and miso soup with liv-
ing cultures) [50,55]. Our study could provide a mechanistic
explanation in that lowering DC serum levels (for instance, by
probiotic therapy) or blocking FXR with Z-guggulsterone
would increase ceramide-induced apoptosis in BCPCs and
reduce growth or spread of the tumor. Alternatively, ceramide
could be directly administered to BCPCs or elevated by treat-
ment with VEGFR2/Flk-1 antagonists. In future studies we will
further investigate the prosurvival cell signaling pathway
induced by DC and test the therapeutic potential of serum DC
reduction in breast cancer.
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